التفاصيل البيبلوغرافية
| العنوان: |
Elevation of Neutrophil-to-Lymphocyte Ratio before First-Line Chemotherapy Predicts a Poor Prognosis for Second-Line Chemotherapy in Gastric Cancer. |
| المؤلفون: |
Inoue, Dai, Sekiguchi, Shuhei, Yamagata, Wataru, Maeda, Gen, Yamada, Daiki, Fujiwara, Shun, Itou, Shiori, Kurihara, Masamichi, Hijioka, Yuko, Shimoji, Kohei, Fujiki, Junko, Nakazono, Ayano, Horike, Hideyuki, Yoshioka, Atsushi, Ogura, Yuki, Hatao, Fumihiko, Imamura, Kazuhiro, Namiki, Shin |
| المصدر: |
Oncology; Mar2019, Vol. 96 Issue 3, p140-146, 7p, 3 Charts, 3 Graphs |
| مصطلحات موضوعية: |
CANCER chemotherapy, HEMOGLOBINS, MULTIVARIATE analysis, NEUTROPHILS, STOMACH tumors, SURVIVAL, TUMOR markers, TUMOR classification, RETROSPECTIVE studies, LEUKOCYTE count, LYMPHOCYTE count, PROGNOSIS |
| مستخلص: |
Objectives: The neutrophil-to-lymphocyte ratio (NLR) has been proposed as an indicator of cancer-related inflammation. The aim of our study was to examine the prognostic value of the NLR for patients with advanced gastric cancer receiving second-line chemotherapy. Methods: The association of overall survival (OS) in second-line chemotherapy and the clinicopathological findings including NLR were analyzed retrospectively. The selection criteria were patients who received second-line chemotherapy between January 2010 and June 2015, had histologically confirmed gastric adenocarcinoma, and were followed up until death or for 180 days or longer. Results: Eighty-six patients met the selection criteria. Multivariate analysis revealed that performance status 2, hemoglobin < 10 g/dL, and NLR before first-line chemotherapy ≥3 were adverse predictive markers. NLR before second-line chemotherapy was not associated with OS. A prognostic model was constructed dividing patients into three groups according to the number of adverse predictive factors: good (no factor), intermediate (one factor), and poor (more than two factors). The median OS for the good, intermediate, and poor groups was 14.3, 7.2, and 4.4 months, respectively (p < 0.001). Conclusions: Patients with advanced gastric cancer with performance status 2, hemoglobin < 10 g/dL, and NLR before first-line chemotherapy ≥3 are not likely to benefit from second-line chemotherapy. [ABSTRACT FROM AUTHOR] |
|
Copyright of Oncology is the property of Karger AG and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
